Turn Therapeutics Pushes Eczema Therapy Into Clinical Trials

In a recent interview with Dermatology Times, Bradley Burnam, founder and CEO of Turn Therapeutics, discussed his company’s evolving work in the field, highlighting the development of a novel formula currently under clinical investigation for patients with moderate to severe eczema.

Burnam shared that his journey began not as an executive, but as a patient searching for more effective treatment options. He discovered and formulated the company’s active pharmaceutical ingredient (API), which initially achieved multiple US Food and Drug Administration (FDA) clearances as a medical device. Building on that foundation, Turn Therapeutics is now expanding its research into therapeutic applications, focusing particularly on dermatologic conditions.

When asked about the company’s approach, Burnam emphasized the importance of understanding mechanisms of action rather than relying solely on anecdotal evidence or preliminary reports. While case observations suggested promising outcomes for moderate to severe eczema, he noted the need for rigorous evaluation. “It wasn’t enough for me to know just that it was working. I wanted to know why,” he explained. This focus reflects a broader effort in dermatology to move beyond surface-level efficacy and establish clearer biological underpinnings for emerging therapies.

Burnam also discussed the dual nature of his company’s innovation pipeline, which balances existing FDA-cleared uses with ongoing trials in dermatology. According to Burnam, early data and prior experience with the API indicated potential anti-inflammatory and antimicrobial properties, spurring further research into its role in eczema management. He highlighted that while enthusiasm around anecdotal reports is valuable, comprehensive clinical studies remain essential to ensuring both safety and reproducibility of outcomes.

Burnam also noted that patient-centered development is a guiding principle for Turn Therapeutics, underscoring that long-term success in dermatology requires not only innovative science but also meaningful improvements in patients’ daily lives. His dual role as a patient and innovator has shaped the company’s trajectory, driving it toward solutions that combine scientific rigor with clinical practicality.

The interview underscored Turn Therapeutics’ commitment to bridging gaps between patient experience, regulatory pathways, and therapeutic development. Burnam’s unique perspective as both a patient and innovator has shaped the company’s trajectory, driving it toward solutions that combine scientific rigor with clinical practicality. If validated in larger trials, the therapy could represent an additional option for patients with moderate to severe disease, an area where unmet needs remain significant.